Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliations: University of Florida Proton Therapy Institute, Jacksonville, Florida (Dr Mendenhall; email@example.com); Mayo Clinic, Rochester, Minnesota (Dr Schild); and Loma Linda University Medical Center, Loma Linda, California (Dr Slater).
To the Editor: Dr Sheets and colleagues1 used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to retrospectively compare surrogate outcomes (claims) for patients with non–metastatic prostate cancer treated with 3 radiation modalities—conformal radiation therapy, IMRT, and proton therapy—advances expected to improve disease control and toxicity outcomes through improved radiation dose distribution.
Mendenhall NP, Schild S, Slater J. Radiation Therapy Modalities for Prostate Cancer. JAMA. 2012;308(5):450. doi:10.1001/jama.2012.8112